Evidence map›Paper›PMID 42296352›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

ModBind

William Sinko, Blake Mertz, Yoh Terada, S Roy Kimura

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

William SinkoAlivexis, Inc., Cambridge, MA 02142.ORCID 0009-0002-9358-9290
Blake MertzAlivexis, Inc., Cambridge, MA 02142.ORCID 0000-0002-7677-0496
Yoh TeradaAlivexis Inc., Minato-ku, Tokyo 105-0004, Japan.ORCID 0009-0004-1602-5111
S Roy KimuraAlivexis, Inc., Cambridge, MA 02142.ORCID 0009-0008-0930-0479

Funding

Alivexis Inc N/AGenerative AI Accelerator Challenge (GENIAC) N/A
6 · The paper itself

Abstract

Recently, we described ModBind, a powerful simulation-based predictor of ligand off-rates and binding free energy. Here, we describe an update to the method-ModBind

Indexed as

Drug DiscoveryProteinsComputer SimulationLigandsProtein BindingThermodynamicsLigandsProteinsbiophysicscomputational chemistrydrug discoverymolecular dynamicsstatistical mechanics

Identifiers

PMID42296352
PMCPMC13291613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.